Review: Application of Bioequivalence Testing of Medicines in Peru

Angel T. Alvarado, Vivian Gray, Ana María Muñoz, María Saravia, María R. Bendezú, Haydee Chávez, Jorge A. García, Roberto Ybañez-Julca, Andres Chonn-Chang, Patricia Basurto, Mario Pineda-Pérez, Alberto Salazar

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

Resumen

This is a review of the current status of drug bioequivalence studies in Peru. A bibliographic search was conducted in PubMed (Medline database) for bioequivalence studies in Peru. Generic drugs constitute the basis of pharmacological requests in health care systems in Latin American countries. Peru has enacted laws and regulations that require bioequivalence studies of high health risk drugs and exemptions, based on international legislation, to be conducted in research centers accredited by the authority of Health. There is a list of 19 drugs that must demonstrate their therapeutic equivalence through in vivo or in vitro studies, of which 13 have shown bioequivalence in vivo, and 8 of those have shown bioequivalence in vitro. There is a challenge for health authorities to enforce the current legislation and an even greater challenge for pharmaceutical laboratories to demonstrate bioequivalence of multi-source drugs with the reference drug.

Idioma originalInglés
Páginas (desde-hasta)220-226
Número de páginas7
PublicaciónDissolution Technologies
Volumen29
N.º4
DOI
EstadoPublicada - 2022

Huella

Profundice en los temas de investigación de 'Review: Application of Bioequivalence Testing of Medicines in Peru'. En conjunto forman una huella única.

Citar esto